


# Teva Innovative Medicine Pipeline




Pipeline is current as of July 2026

1. In collaboration with MODAG.
2. Submitted to FDA December 2025, submitted to EMA April 2026
3. Submitted to FDA June 2026
4. In collaboration with Launch Therapeutics
5. In collaboration with Sanofi

Teva innovative medicine pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

# Teva Biosimilar Franchise



Pipeline is current as of July 2026

1. In collaboration with Alvotech for the U.S. Market 2. In collaboration with Polpharma 3. In collaboration with mAbxience 4. Launched regional in Europe and under regulatory review in US 5. Launched regional in Europe and approved in US 6. In collaboration with Celltrion in the U.S. and Canada 7. In collaboration with BioEq in the UK (marketed as ONGAVIA®), in the EU (marketed as RANIVISIO®) and in Canada (marketed as RANOPTO®) 8. In collaboration with Samsung Bioepis in the U.S.

Teva biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.